Bayer has announced plans to acquire Perfuse Therapeutics. The move aims to strengthen its ophthalmology pipeline. It shows how Bayer is dedicated to developing drugs for eye-related disorders.
This acquisition will increase Bayer’s product range in retinal treatments. It will allow the development of new treatment methods for diseases that threaten people’s sight. Moreover, it will improve Bayer’s research abilities in ophthalmology. This means that patients will have more effective treatment choices. Perfuse Therapeutics is experienced in developing vascular treatment techniques. Their technology allows for better blood circulation in the eyes. In addition, their methods treat conditions caused by retinal ischemia. This aligns with Bayer’s strategy to address unmet medical needs.
“We are excited by the work of the team at Perfuse Therapeutics and encouraged by the potential of PER-001,” said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer Pharmaceuticals. “With this acquisition, we are complementing our expertise in ophthalmology and our pipeline, reinforcing our commitment to developing urgently needed therapies for patients.”
Advancing Innovation in Ophthalmology
The transaction is also expected to boost Bayer’s future development in healthcare innovations. It boosts its involvement in the biotechnology industry. Moreover, it facilitates faster innovation in the field of ophthalmology drugs. Thus, Bayer will be able to enhance its global influence on the healthcare industry. According to a spokesperson at Perfuse Therapeutics, the cooperation between the two companies will result in numerous advantages. First, it may facilitate faster clinical trials. Also, both organizations will be able to combine their expertise efficiently. This merger highlights the increasing interest in biotechnological innovation in the field of ophthalmology.
“I’m incredibly proud of what the Perfuse team has accomplished and deeply thankful to all our investors and collaborators,” said Sevgi Gurkan, MD, Founder and CEO of Perfuse Therapeutics, Inc. “Bayer’s vision aligns closely with ours, and they have the scale and global resources to unlock the full potential of PER-001 to change the trajectory of human blindness. We are very excited to see our mission continue with even greater momentum.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
